ClinicalTrials.gg
Active, not recruitingNCT07151924CALI-BFUpdated Sep 24, 2025

Eating Disturbances in Patients With Type 1 Diabetes Initiating Insulin Therapy

An observational study in Diabete Type 1, sponsored by University Hospital, Toulouse. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by University Hospital, Toulouse · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Feeding and Eating Disorders with a site in France — 11 open to participants now, 14 under way, none of them phase 3. Feeding and Eating Disorders · France.

Planned enrollment
15th of 29
100 · median 100
Started
2025
with 7 others
Observational
29 of 49
7 open now
Primary completion
2027-02
later than 9 of 13 live
Registered
45th of 49
by date

Among the 49 studies in Feeding and Eating Disorders with a site in France, this one is the 15th largest by planned enrollment of the 29 observational ones that give a count, is one of 8 that started in 2025, is one of 29 observational ones, reaches primary completion later than 9 of the 13 other live ones, and was the 45th registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

11 of the 49 studies in Feeding and Eating Disorders with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Feeding and Eating Disorders with a site in France, or all of them as a file.
02

Study summary

The prevalence of eating disorders is particularly high among people with type 1 diabetes (T1D). These abnormalities, such as "diabulimia," are frequently responsible for poor insulin therapy management and, consequently, chronic glycemic imbalance, exposing them to an increased risk of complications. Their detection and management unfortunately remain insufficient in current practice.

However, to date, no study has addressed the question of the prevalence and impact of eating disorders in this context. Our research hypotheses are therefore as follows:

  1. The existence of an eating disorder is likely frequently overlooked and, therefore, not taken into account in patients with T1D initiating semi-automated insulin therapy with BF.
  2. The existence of an eating disorder could impair the performance of the BF device in terms of improving glycemic control in patients with T1D initiating this treatment method.

Patients clinical characteristics, glycemic monitoring parameters ad questionnaires answers will be recorded. The prevalence of eating disorders will be calculated, and the association between the presence of these abnormalities and baseline clinical characteristics and glycemic control parameters will be analyzed.

Read the detailed description

The prevalence of eating disorders (EDs) and problematic eating behaviors (PEBs) is particularly high among people with type 1 diabetes (T1D), affecting 20 to 50% of women and 5 to 25% of men among young patients. These abnormalities, such as "diabulimia," are frequently responsible for poor insulin therapy management and, consequently, chronic glycemic imbalance, exposing them to an increased risk of complications. Their detection and management unfortunately remain insufficient in current practice.

The treatment of T1D is currently undergoing a veritable technological revolution linked to the arrival of the first semi-automated insulin therapy devices (or closed loop, LF). The use of these devices most often makes it possible to achieve recommended glycemic control targets (HbA1c, continuous glucose monitoring [CGM] data), reduce glycemic variability, and avoid hypoglycemia. Insulin administration is based on the data transmitted: food intake and quantity of carbohydrates consumed. The role of dietitians is therefore crucial in the therapeutic education of patients and the care pathway imposed by the initiation of this new treatment method. It is likely that many patients initiating automated insulin therapy with BF present an eating disorder or CAP that may interfere with the management of the device.

However, to date, no study has addressed the question of the prevalence and impact of eating disorders and CAP in this context. In the absence of available data, national and international recommendation texts dedicated to insulin therapy with BF do not specify appropriate conduct for patients presenting with these eating disorders. Our research hypotheses are therefore as follows:

  1. The existence of an eating disorder (ED and/or CAP) is likely frequently overlooked and, therefore, not taken into account in patients with T1D initiating semi-automated insulin therapy with BF.
  2. The existence of an eating disorder (ED and/or CAP) could impair the performance of the BF device in terms of improving glycemic control in patients with T1D initiating this treatment method.

Patients clinical characteristics and glycemic monitoring parameters (HbA1c and CGM data), available as part of routine care, will be recorded in an electronic case report (REDCap software). The mSCOFF and QACD questionnaires will be administered during the dietary interview preceding BF device implantation, and responses will be collected. The prevalence of eating disorders will be calculated, and the association between the presence of these abnormalities and baseline clinical characteristics and glycemic control parameters will be analyzed.

The care pathway established for initiating BF treatment requires a follow-up medical consultation at 3 months, followed by a consultation at 6 months. As part of the study, visits at 3 months (12 ± 2 weeks) and 6 months (24 ± 4 weeks) will be scheduled and will include an interview with a dietitian, to collect glycemic control parameters (at 3 and 6 months), measure body weight (at 3 and 6 months), and repeat the mSCOFF and QACD questionnaires (at 6 months). Data on the evolution of glycemic control and variability parameters, weight and mSCOFF and QACD scores will be analyzed in the overall study population, then according to the existence or not of disturbances in eating behavior at inclusion.

03

Conditions studied

  • Diabete Type 1

Keywords

  • diabete type 1
  • eating disorders
  • eating
  • insulin
  • insulin therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with type 1 diabetes for whom closed-loop insulin therapy has been recommended

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient diagnosed with type 1 diabetes.
  • Patient with a CGM device for more than 3 months with > 80% of data captured in the last month.
  • Indication for the implementation of a BF device as part of routine care, in the Diabetology, Metabolic Diseases and Nutrition Department of the Toulouse University Hospital (initiating center).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women, or those planning to become pregnant within 6 months of inclusion.
  • History of obesity surgery or a preparatory program for obesity surgery planned during the study period.
  • Pharmacological treatment likely to significantly influence food intake and body weight, whether ongoing or discontinued within the last 3 months (e.g., GLP-1R agonist): Liraglutide (Victoza®, Saxenda®), Semaglutide (Ozempic®, Wegovy®), Dulaglutide (Trulicity®), Tirzepatde (Mounjaro®), Orlistat (Xenical®)
  • Eating disorder requiring specific treatment in the previous 12 months.
  • Refusal or inability to consent to participate.
  • Persons under legal protection (guardianship, curatorship, or court-ordered protection).
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Patients with type 1 diabete

    Patients with type 1 diabete with closed-loop therapy

    Other: Questionnaires answers · Other: Biological assessment

Interventions

  • OtherQuestionnaires answers

    Patients will be asked to complete the MScoff and QACD questionnaires during interviews with the dietitian at baseline, 3 months and 6 months.

  • OtherBiological assessment

    Collection of HbA1c level and continuous glucose monitoring data

06

What researchers measure

Primary outcomes

  1. Prevalence of eating disorders

    The primary outcome measure for establishing the prevalence of eating disorders is a composite outcome measure based on determining the existence of eating disorders \[ED\] by analyzing responses to the mSCOFF questionnaire (score ≥ 2) and/or problematic eating behaviors \[PEB\] by analyzing responses to the QACD questionnaire (score ≥ 20).

    Time frame: 6 months after the inclusion

Secondary outcomes

  1. Prevalence of eating disorders (EDs)

    Prevalence of EDs (mSCOFF score ≥ 2 and QACD ≥ 20)

    Time frame: 6 months after the inclusion

  2. Clinical characteristics at inclusion

    Measurement of clinical characteristics at inclusion: age

    Time frame: 6 months after the inclusion

  3. Clinical characteristics at inclusion

    Measurement of clinical characteristics at inclusion: sex

    Time frame: 6 months after the inclusion

  4. Clinical characteristics at inclusion

    Measurement of clinical characteristics at inclusion: weight in kg and height in cm which will be combined to calculate the BMI (kg/m²)

    Time frame: 6 months after the inclusion

  5. Clinical characteristics at inclusion

    Measurement of clinical characteristics at inclusion: medical history

    Time frame: 6 months after the inclusion

  6. Clinical characteristics at inclusion

    Measurement of clinical characteristics at inclusion: treatments

    Time frame: 6 months after the inclusion

  7. Description of glycemic control at inclusion

    Measurement of basic glycemic control : Hba1c average

    Time frame: 6 months after the inclusion

  8. Description of variability indicators at inclusion

    Measurement of basic glycemic variability parameters : continuous glucose measurement data

    Time frame: 6 months after the inclusion

  9. Evolution of biological parameters of glycemic variability between the inclusion visit and the follow-up visits

    Measurement of the variation in blood glycemic variability (continuous glucose measurement data) parameters between the inclusion visit and the different follow-up visits (3 months and 6 months)

    Time frame: 6 months after the inclusion

  10. Evolution of biological control parameters variability between the inclusion visit and the follow-up visits

    Measurement of the variation in blood control parameters variability (HbA1c) between the inclusion visit and the different follow-up visits (3 months and 6 months)

    Time frame: 6 months after the inclusion

  11. Evolution of BMI between inclusion and follow-up visits

    Change in BMI between the baseline visit and the 3-month and 6-month follow-up visits

    Time frame: 6 months after the inclusion

  12. Evolution of body weight between inclusion and follow-up visits

    Change in body weight between the baseline visit and the 3-month and 6-month follow-up visits

    Time frame: 6 months after the inclusion

  13. Change in questionnaires scores between baseline and follow-up

    Change in mSCOFF (Sick, control, one stone, fat, food) scores between the baseline visit and the 6-month follow-up visit

    Time frame: 6 months after the inclusion

  14. Change in questionnaires scores between baseline and follow-up

    Change in QACD (questionnaires of attitudes and behaviors related to diabetes management) scores between the baseline visit and the 6-month follow-up visit

    Time frame: 6 months after the inclusion

07

Study locations

1 site
  • Diabetology, Metabolic Diseases and Nutrition Department Rangueil Hospital, Toulouse University Hospital 1 avenue du Pr Jean Poulhès
    Toulouse, 31059, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.

Of 61 non-industry observational studies under Feeding and Eating Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 95. This study's planned 17 months is below that.

Counting every sponsor, half of 64 studies reached it within 42 months; a quarter within 18 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Sep 3, 2025
StartActual
Sep 4, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07151924
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Sep 4, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Sep 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion